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ABSTRACT
Normal homeostasis of adult intestinal epithelium and repair following tissue 
damage is maintained by a balance of stem and differentiated cells, many of which are 
still only poorly characterised. Enteroendocrine cells of the gut are a small population 
of differentiated, secretory cells that are critical for integrating nutrient sensing 
with metabolic responses, dispersed amongst other epithelial cells. Recent evidence 
suggests that sub-sets of secretory enteroendocrine cells can act as reserve stem cells. 
Given the link between cells with stem-like properties and cancer, it is important that 
we identify factors that might provide a bridge between the two. Here, we identify 
a sub-set of chromogranin A-positive enteroendocrine cells that are positive for the 
developmental and cancer-associated transcription factor Brachyury in normal human 
small intestinal and colonic crypts. Whilst chromogranin A-positive enteroendocrine 
cells are also Brachyury-positive in colorectal tumours, expression of Brachyury 
becomes more diffuse in these samples, suggesting a more widespread function in 
cancer. The finding of the developmental transcription factor Brachyury in normal 
adult human intestinal crypts may extend the functional complexity of enteroendocrine 
cells and serves as a platform for assessment of the molecular processes of intestinal 
homeostasis that underpins our understanding of human health, cancer and aging.
INTRODUCTION
The adult intestinal epithelium is one of the most 
rapidly self-renewing tissues of the body, giving rise 
to differentiated cells for digestion and absorption 
of food. Constant insult from luminal contents in the 
gut necessitates continuous turnover and renewal of 
differentiated epithelial cells that carry out homeostatic 
functions, including cells of the absorptive and secretory 
lineages. Whilst rare (~1% of crypt cells), enteroendocrine 
cells (EECs), which can be divided into specific EEC 
sub- groups, are central to this process through their 
secretion of hormones [1]. Continuous replacement 
of differentiated cells is brought about by multipotent 
stem cells (SCs), which predominantly reside in the 
crypt-base [Lgr5-marked crypt-base columnar cells], 
and their proliferating progenitor-derivatives [transient 
amplifying (TA) cells] [2, 3]. However, the adult 
intestinal SC compartment is more complex in nature, 
additionally comprising of poorly understood sub-types 
of SCs, some rapidly cycling, others quiescent and more 
damage resistant (e.g., Bmi1/Hopx/Tert/Lrig1-marked). 
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One function for the additional sub-types is that they act 
as reserves that can replace rapidly cycling Lgr5-SCs 
after injury or with age [4]. The plasticity of these cells 
in response to various cues is unclear; cell types have 
been identified with SC capacity which are derived from 
progenitors or differentiated cell types. For example, a 
sub-set of post-mitotic (non-proliferating) EECs [marked 
as Chromogranin A (ChgA)-positive/Ki67-negative] has 
been found at the crypt-base of the mouse small intestine 
and these cells demonstrate SC markers such as Lgr5 
[5]. Furthermore, the transcription factor Sox9 is present 
in the SC/progenitor zone of the mouse small intestine 
where it regulates proliferation and differentiation in a 
dose-dependent manner; Lgr5-SCs are Sox9-low, but 
a population of differentiated EECs expressing ChgA 
shows high levels of Sox9. This latter population is 
Ki67-negative (therefore post-mitotic) but does have 
regenerative capacity following radiation damage [6, 7].
It is possible that different sub-sets of reserve SCs 
exist in the intestinal crypt, determined by the presence 
of specific transcription factors such as Sox9 and others, 
not yet determined. The importance of EECs to crypt 
homeostasis is further highlighted by recent studies which 
show that intestinal SC divisions in Drosophila mid-gut 
are stimulated by EECs [8]. Taken together, sub-groups of 
EECs might play diverse and critical functions in normal 
gut homeostasis, in regeneration following damage and 
during aging. 
The link between stem and progenitor cells and 
colorectal cancer (CRC) is established [9, 10], and 
like normal intestinal epithelium, cancers consist of a 
heterogeneous mix of cells including stem-like cells that are 
the source of cells within the tumour. Stem-like cancer cells 
(CSCs) in CRC are marked by Lgr5 [11] and such Lgr5-
marked CSCs are present at high levels in human adenomas 
and invading cells [12]. CRCs have also been shown 
to contain ChgA-positive endocrine cells and a worse 
prognosis may be associated with endocrine differentiation 
[13]. Furthermore, neuroendocrine differentiation in CRCs 
has been highlighted as an independent prognostic factor in 
stage III–IV disease [14].
Brachyury is a developmentally regulated T-box 
transcription factor involved in controlling cell movements 
and differentiation [15]. Outside its developmental context, 
aberrant expression of Brachyury is associated with a 
number of solid tumour types, including CRC [16, 17], 
cancer SCs [18] and also poor prognosis [19]. Brachyury 
was also shown to be necessary for spermatogonial SC 
fate in adult mouse testis where it is critically required for 
germline SC maintenance and self-renewal [20].
We show here that the developmental and cancer-
associated transcription factor Brachyury identifies a 
sub-population of EECs in normal adult human intestinal 
crypts, adding further depth and complexity to the 
function of this group of cells in adult intestinal crypts. 
Furthermore, Brachyury continues to mark this group of 
EECs in colorectal tumours, but its expression becomes 
more widely distributed, suggesting a more diverse 
function in cancer.
RESULTS
Brachyury is expressed in adult, normal 
intestinal tissue
Given the function of Brachyury in SCs of mouse 
testis and its association with cancer, we wanted to 
confirm the expression profile of Brachyury in normal 
adult human tissues, including the testis, and whether it 
exhibited a Cancer Testis Antigen-gene (CTA-gene)-like 
profile; that is, expressed in only normal adult immune-
privileged tissues (i.e. testis and brain) and aberrantly in 
cancers [21]. We therefore performed qRT-PCR analysis 
of Brachyury on a range of normal tissues (Figure 1). 
The expression pattern observed loosely follows a CTA/
central nervous system gene expression profile (with the 
exception of SC-rich bone marrow), that is, high levels 
in testis and brain of normal tissues. However, we also 
observed low level Brachyury expression in the colon and 
small intestine (amongst other tissues), extending existing 
studies [22] (see also Supplementary Figures 1A, 2B, 3C) 
suggesting a wider function for Brachyury in a more 
extensive group of adult somatic cells. 
Brachyury marks a sub-group of non-
proliferating ChgA-EECs in adult intestinal 
crypts
We explored this expression further by immuno-
staining in human adult intestinal tissue. To this end, 
we validated the specificity of the anti-Brachyury 
monoclonal antibody (ab140661) using siRNA-mediated 
Brachyury-depletion in cancer cells (Supplementary 
Figure 2A, 2B). Using this antibody, we demonstrate 
that strong cytoplasmic Brachyury staining is present in 
a small cohort of cells within the normal human colonic 
crypt and small intestine (Figure 2A–2E; see also SI for 
source of ‘normal’ tissue). [Note: this strong cytoplasmic 
staining is very distinct from weaker cytoplasmic staining 
that we sometimes observed, and only strong staining 
is considered here]. Remarkably, most crypts contain 
at least one strongly Brachyury-positive cell in the SC 
compartment. Some crypts also contain Brachyury-
positive cells in the TA zone of the crypt and more rarely 
towards the luminal surface (Figure 2F). [Similar results 
were obtained using another previously validated anti-
Brachyury antibody (ab57480) [16], data not shown; and 
anti-Brachyury antibody (sc-20109) [23], data not shown]. 
Brachyury-positive cells had the morphology and location 
of EECs, that is, adjacent to the crypt-basement membrane 
with an abluminal disposition and located mainly at the 
crypt-base. Frequent overlap is observed between strongly 
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stained Brachyury-positive cells and ChgA, a marker of 
differentiated EECs (Figure 3A, 3B). However, not all 
ChgA-positive cells are Brachyury-positive and it appears 
that Brachyury-positive cells are a distinct sub-population 
of EECs. Interestingly we observed that in the colon 
(Figure 3A), most ChgA-positive cells are Brachyury-
positive whereas in the small intestine (Figure 3B) 
there are more ChgA-positive cells that are negative for 
Brachyury. 
Cells that were positive for the post-mitotic EEC 
marker ChgA, were found to be negative for the nuclear 
localised proliferation marker Ki67 (Figure 3E, 3F), 
indicating that these cells are unlikely to be proliferating. 
[However, we noted a co-localisation between strong 
Brachyury positive cells and cytoplasmic localised Ki67 
when we used an alternative Ki67 antibody, ab15580 
(Supplementary Figure 4); although the significance of 
this cytoplasmic localisation is unclear]. 
Given that in the mouse, a population of 
differentiated EECs with regenerative capacity (ChgA-
positive, Ki67-negative) express high levels of Sox9, 
we explored whether the Brachyury-positive EECs we 
have identified are similarly marked as Sox9-high. We 
found that Brachyury-positive cells in the crypt are Sox9-
negative (or sub-low) (Figure 3C, 3D) so in this respect, 
are not similar to the Sox9-high EECs seen in mouse SI 
crypts [6, 7]. It is interesting to note however, that like 
Sox9, Brachyury can act in a dose-dependent manner [15] 
and this may be an important functional feature of such 
transcription factors in EECs. 
The association between Brachyury and ChgA is 
maintained in occasional cells in CRCs
We then asked whether the association between 
Brachyury- and ChgA-positive cells was maintained 
in CRC patient derived material. Initially, we studied 
mRNA microarray data sets from four different sources 
(see Supplementary Information 1) to determine whether 
there was a correlation between Brachyury and ChgA 
expression in normal colon and in CRC tissues.  A positive 
correlation between Brachyury and ChgA was observed 
Figure 1: Brachyury is present in normal adult colon and small intestine. qRT-PCR analysis of Brachyury in normal human 
tissues showing low level expression in colon and small intestine. Results were normalised to a combination of two endogenous reference 
genes (GAPDH/HSPCB). ‘Normalised Fold Change’ represents gene expression relative to the lowest value observed i.e. skeletal muscle 
which is set at ‘1’. Error bars show standard error of the mean.
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in all data sets for normal colon (Figure 4), in accordance 
with our immuno-detection observations. However, we did 
not observe a positive correlation between Brachyury and 
ChgA in three out of the four data sets from CRC tissue 
(Figure 4). To resolve this further, co-IF was carried out on 
patient derived CRC material to determine the localisation 
patterns of Brachyury and ChgA within tumours. Three 
out of five of the cancers studied were Brachyury-positive 
but ChgA-negative (data not shown). Two tumours stained 
positively for both Brachyury and ChgA (example shown 
in Figure 5). Staining of Brachyury within the tumour 
is broad and heterogeneous with occasional cells that 
are dual stained for both Brachyury (strongly stained 
cells) and ChgA (Figure 5). It appears that the staining 
Figure 2: Immuno-detection of Brachyury in normal human intestinal crypts. (A) Brachyury-IF on normal right-side colon 
FFPE sections; DAPI staining, blue; Brachyury staining green/ab140661. (B, C) Brachyury-IHC staining/ab140661 in normal human 
colon crypts (×20). Red arrows in B illustrate Brachyury-positive cells at crypt-base (consistent with SC zone), some crypts contain 
single Brachyury-positive cells in the TA zone (indicated by red arrows in (C). (D) Brachyury-IF: normal small intestinal FFPE sections. 
(E) Brachyury-IHC in normal human small intestine (×20). (F) Schematic diagram illustrating the mean number of Brachyury positive 
cells in three ‘zones’ per colonic crypt. Zone 1 encompasses the stem cell compartment, zone 2 encompasses the TA region and zone 
3 encompasses the region containing differentiated cells (See Supplementary Figure 3 for classification of zones 1-3). The number of 
Brachyury positive cells in single crypts were scored and then a mean value calculated (and standard deviation) for each of the three zones. 
A total of 1930 pathologically normal crypts were counted from 22 independent patient derived samples (See SI for ‘normal’ tissue source 
information). FFPE: formalin-fixed paraffin-embedded.
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of Brachyury in the tumour is more diffuse than in 
normal tissue, suggesting broad functions of Brachyury 
in response to tumour-associated signals. This broader 
staining pattern for Brachyury in CRCs might explain why 
the association between Brachyury and ChgA observed 
earlier, is lost in the microarray analysis. Cells that are 
dual stained for Brachyury and ChgA are always strongly 
stained for Brachyury.
Figure 3: Immuno-detection of Brachyury in normal human intestinal crypts. (A) co-IF for Brachyury/ChgA on normal 
colon crypt FFPE sections. Brachyury/ChgA-positive cells are located at the crypt-base (consistent with SC zone), some contain single 
Brachyury/ChgA-positive cells in the TA zone. (B) Brachyury/ChgA in the small intestine. (C) co-IF for Brachyury/SOX9 on normal colon 
crypt FFPE sections. (D) Brachyury/SOX9 in the small intestine. (E) co-IF for Brachyury/Ki67 (ab16667) in normal colon crypt FFPE 
sections. (F) Brachyury/Ki67 in the small intestine. For A-F, DAPI staining, blue; Brachyury staining, green/ab140661; ChgA/Sox9/Ki67 
staining, red.
Oncotarget11483www.impactjournals.com/oncotarget
Figure 4: Microarray co-expression analyses between ChgA and Brachyury in normal and colorectal carcinoma tissues. 
mRNA microarray expression for Brachyury (T) and ChgA were extracted from four independent datasets (Hong, TCGA, Gaspar and 
Gaedcke; See Supplementary Information 1) that have information for normal and colorectal cancer (CRC) samples. Pearson r correlation 
was used to evaluate the association between the expression levels of Brachyury and ChgA in the normal and in the CRC samples. In silico 
analysis indicates a direct correlation (Pearson r > 0.2) between Brachyury and ChgA expression in normal samples (blue line) for all 
datasets studied. In CRC samples (black line) no association was observed (−0.2 < Pearson r < 0.2) in three of the datasets (Hong, TCGA 
and Gaspar datasets) with the exception of the Gaedcke dataset that presents a direct association between Brachyury and ChgA (Pearson 
r > 0.2). Expression is present as log2 median-centered intensity values for each probe per study (original values extracted from Oncomine 
database). Each blue triangle represents a normal sample and each black square a CRC sample. ‘n’ represents the total number of samples 
in each dataset.
Figure 5: Immuno-detection of Brachyury and ChgA in poorly differentiated pT3N0 adenocarcinoma CRC tissue. 
co-IF for Brachyury/ChgA on CRC FFPE section; DAPI labelled in blue, Brachyury labelled in green and ChgA in red. Strongly Brachyury 
stained cells are co-incident with cells being labelled with ChgA. 
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DISCUSSION
In the present study, we have identified a previously 
uncharacterised sub-set of Brachyury and ChgA-positive 
EECs in adult human small intestinal and colonic crypts. 
Evidence is mounting to suggest that sub-groups of 
EECs might be involved in SC homeostasis and/or crypt 
regeneration. In support of this, recent RNA-seq/GO 
cluster analysis from our group suggests Brachyury is 
involved in somatic SC maintenance [16]. It is interesting 
to speculate that Brachyury is required for a sub-set of 
secretory lineage EECs in intestinal crypts that have 
plasticity and may modulate the activity of surrounding 
cells, possibly even acting as (reserve) SCs, similar to 
other known examples. 
As mentioned previously, intestinal SCs have 
been shown to give rise to tumours [9, 10] and the link 
between SCs and CSCs has now been shown for many 
different tumour types, including CRC [24, 25]. We have 
shown previously that Brachyury is correlated with CRC 
cells that have CSC characteristics [18]; furthermore, 
Brachyury has been shown to be required for maintenance 
of spermatogonial SCs [20] demonstrating its importance 
in maintaining different somatic SC populations. Similar 
to the association of Brachyury with SCs, sub-populations 
of EECs are correlated with reserve SC characteristics, as 
described above. Taken together, it is possible that cells 
marked jointly by Brachyury and ChgA might represent a 
population of cells within the tumour that can demonstrate 
CSC properties which include tumour aggressiveness, 
drug resistance, renewal, EMT and invasion [25, 26]. 
ChgA signals have been linked to tumour aggressiveness 
in prostate cancer, where the presence of proteins/hormones 
produced from neuroendocrine cells may act as growth factors 
contributing to paracrine effects on surrounding stromal cells 
[27]. Furthermore, CRCs displaying endocrine differentiation 
have been reported to have a worse prognosis [13]. We 
showed that the association between Brachyury and ChgA 
marked cells continues beyond cells of the normal intestinal 
crypts and is seen also in CRC tissue. Here, Brachyury is more 
widely dispersed than ChgA, suggesting that Brachyury may 
have broader ranging functions in different regions of the 
tumour, possibly responding to regional tumour associated 
signals. However, given the link between Brachyury, SCs 
[20] and CSCs [18], and ChgA with SCs, it is possible that the 
Brachyury/ChgA-positive cells observed in regions of CRCs 
represent regions rich in CSCs. 
There is mounting evidence that factors involved in 
regulating EMT are also involved in SC biology [28] and 
Brachyury has previously been shown to induce EMT in 
cancer [29]. Brachyury may serve as another example of 
such a regulator of EMT, possibly also then being linked 
to SCs in the normal crypt and CSCs; particularly since 
such factors seem to act in a dose-dependent manner 
such as Twist where low levels promote stemness and 
proliferation and high levels promote EMT [30].
The novel identification of a sub-class of ChgA-
positive, Brachyury-positive EECs in adult, normal 
intestinal crypts and CRC cells provides an intriguing 
platform for further studies associated with normal 
homeostasis and cancer biology.
MATERIALS AND METHODS 
Cell culture
Cell lines, growth conditions and details of 
authentication reports for cell lines used in this study are 
provided in Supplementary Information 1.
Quantitative real-time PCR
cDNA was generated from the total RNA prepared 
from 16 normal human tissues using Quantitect Reverse 
Transcription kit (Qiagen, #205310). Real-time PCR 
reactions were carried out in triplicate on a CFX96 
Real-Time System C1000 Thermal Cycler (BioRad) 
using Quantifast SYBR green RT-PCR kit (Qiagen, 
#204154). Primers used and further details are provided 
in Supplementary Information 1.
Brachyury-knockdown
Brachyury siRNA (Qiagen, SI04133521, SI04144483) 
and negative control siRNA (Qiagen, 1027280) was used at 
a final concentration of 5 nM. Transfection was carried out 
with HiPerFect Reagent (Qiagen, 301705) according to the 
manufacturer’s instructions. Cells were harvested 24 hours 
post-transfection. Details of Brachyury over-expression are 
provided in Supplementary Information 1.
Western blotting
Western blotting protocols, antibodies and antibody 
dilutions used are described in detail in Supplementary 
Information 1. 
Immunohistochemistry (IHC) and 
immunofluorescence (IF)
Detailed protocols are provided in Supplementary 
Information 1, including tables of primary and secondary 
antibodies and relevant dilutions.
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